Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics Inc (VVOS) provides innovative solutions for sleep-disordered breathing through its proprietary oral appliance therapy and integrated clinical protocols. This news hub offers investors and healthcare professionals direct access to official announcements, financial disclosures, and progress updates on the company's non-invasive treatment alternatives for obstructive sleep apnea.
Our curated collection features regulatory filings, partnership announcements, clinical trial updates, and technology developments. Users will find timely information about the Vivos System implementation, insurance coverage expansions, and research collaborations within the sleep medicine field.
The page organizes content by key categories including quarterly earnings reports, FDA communications, provider network growth, and peer-reviewed study publications. Each update maintains factual accuracy while highlighting the company's position in the $7 billion sleep apnea treatment market.
Bookmark this page for streamlined tracking of Vivos' progress in commercializing its oral appliance technology and expanding its licensed provider network. Check regularly for new developments in patient outcomes data and healthcare provider adoption rates across North America.
Vivos Therapeutics reported its financial results for Q4 and full year 2022 with revenue of $4.0 million in Q4 and $16.0 million for the full year, compared to $4.4 million and $16.9 million in the previous year. The company completed a capital raise of approximately $7.4 million in January 2023. Gross profit decreased to $2.4 million in Q4, down from $3.1 million in 2021, reflecting increased costs. Vivos also acquired patents from Advanced Facialdontics, enhancing its portfolio for treating sleep disorders. The company aims for revenue growth in 2023 through expanded product offerings and partnerships.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is set to release its fourth quarter and full year 2022 financial results after market close on March 30, 2023. This announcement will be followed by a conference call at 5:00 PM ET to discuss the results and recent milestones. Vivos specializes in medical devices for treating sleep disorders, particularly obstructive sleep apnea (OSA) and snoring, through its proprietary oral appliances. The company has treated over 33,000 patients globally, showcasing the effectiveness of its noninvasive Vivos Method, developed by trained dentists. The company emphasizes its commitment to innovation in the sleep disorder treatment sector.
Vivos Therapeutics (NASDAQ: VVOS) announced that CEO Kirk Huntsman and CFO Brad Amman will speak at the 35th Annual ROTH Conference on March 14, 2023, at 1:30 PM PT. The event will be held both virtually and in-person in Dana Point, CA, from March 12-14, 2023. They will participate in a fireside chat and conduct one-on-one meetings with investors. The Vivos Method offers a non-invasive solution for mild-to-moderate obstructive sleep apnea (OSA) and snoring, having treated approximately 31,000 patients globally. More details can be found on their investor relations page.
Vivos Therapeutics (NASDAQ: VVOS) announced the acquisition of patents and product rights from Advanced Facialdontics, enhancing its offerings for treating obstructive sleep apnea (OSA) and related conditions. This includes the Preventive Oral Device (POD®) for Temporomandibular Joint Dysfunction (TMD) and the Night Block for alleviating traditional treatment downsides. The acquisition broadens Vivos' patent portfolio and aims to open new revenue streams, targeting millions suffering from TMD and Bruxism. CEO Kirk Huntsman emphasized the strategic importance, stating it allows for a complete range of products at competitive prices, enhancing market position.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
